Roche beefs up diagnostic arm with another bet on faster, cheaper DNA sequencing
While Roche pours half a billion dollars into its Covid-19 antibody test, the Swiss company is quietly beefing up the rest of their diagnostics arm.
Roche today acquired Stratos Genomics, a Seattle-based developer of a new DNA technology designed to make genetic strands more easy to read. Roche said it will use the Stratos technology, alongside its existing efforts, to develop a nanopore sequencing device that can quickly and cheaply read patients’ DNA in clinics to diagnosis disease and assess the risk of developing one.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.